Related Experiment Video
Updated: May 14, 2026
11:35
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Multiple sclerosis spasticity daily management: retrospective data from Europe
1Neuroimmunological and Multiple Sclerosis Clinic and Research Unit, Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. thomas.berger@i-med.ac.at
Expert Review of Neurotherapeutics
|February 2, 2013
Summary
Multiple sclerosis (MS) spasticity is common and debilitating, yet undertreated. New treatments are needed to improve patient quality of life and reduce healthcare costs associated with MS-related disability.
Area of Science:
- Neurology
- Neuroscience
Background:
- Multiple sclerosis (MS) is a progressive neurological disease.
- Spasticity is a common and disabling symptom in MS patients.
- Current treatments for MS spasticity are often inadequate.
Purpose of the Study:
- To highlight the prevalence and impact of spasticity in MS.
- To discuss the undertreatment of MS spasticity.
- To emphasize the need for improved therapeutic options.
Main Methods:
- Review of epidemiological data from Spain (6E, 5E studies) and Germany (MOVE 1 study).
- Analysis of the impact of spasticity on patient quality of life and daily living.
- Assessment of the healthcare and societal costs associated with MS spasticity.
Main Results:
- MS spasticity is frequently occurring and increases with disease progression.
- Inadequate treatment control of spasticity negatively impacts patients.
- Moderate-to-severe spasticity is linked to increased disability and significant healthcare costs.
Conclusions:
- Effective management of MS spasticity is crucial for patient care.
- There is a significant unmet need for better spasticity treatments in MS.
- Newer pharmacological interventions could offer improved symptomatic relief and potentially slow disability progression.
